Most GLP-1 prescribers in Chandigarh are general physicians or aesthetic clinics. Gini offers the only endocrinologist-led, data-driven GLP-1 programme in the Tricity. Dr. Anil Bhansali (former Head of Endocrinology, PGIMER Chandigarh) leads the programme from Sector 69, Mohali — 15 minutes from central Chandigarh.
📍 Sector 69, Mohali · OPD: 0172 4120100 · Mon–Sat 10 AM–6 PM
Gini Advanced Care Hospital is in Sector 69, Mohali — directly accessible from all major Chandigarh localities via VIP Road and the Phase 7 corridor.
OPD Hours: Mon–Sat 10 AM–6 PM. Many Chandigarh patients combine GLP-1 consultations with lab tests at Gini's in-house NABH-accredited lab — no separate lab visit needed. HbA1c, thyroid, kidney function, lipid profile, Echo, and TMT are all available same-day.
GLP-1 drugs are powerful medicines that act on multiple organ systems. Prescribing them without proper assessment is a clinical risk — not just an inconvenience.
Wrong drug selection for your metabolic profile. Mounjaro (dual GIP/GLP-1) and Ozempic (GLP-1 only) have different indications depending on insulin secretion, body composition, and glucose pattern. A GP cannot distinguish between them clinically.
GLP-1 drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. General practitioners often skip thyroid C-cell history screening — a serious omission.
GLP-1 drugs affect heart rate — semaglutide increases resting heart rate by 2–4 bpm on average. For patients with existing cardiac risk factors, an Echo or TMT baseline is required before starting. This is routinely skipped outside specialist settings.
Weight loss alone is not a treatment outcome. You need to know if your HbA1c, lipid profile, kidney function, and metabolic markers are improving. Without quarterly monitoring, you are flying blind on the most important question: is the treatment working?
At Gini, every GLP-1 patient undergoes a full metabolic and safety assessment before prescription. Dr. Bhansali's programme tracks outcomes quarterly. This is endocrinology — not a weight loss service.
Dr. Bhansali selects the right GLP-1 drug based on your metabolic phenotype, HbA1c, cardiac status, and cost considerations — not patient preference alone.
For the full drug directory including domestic generics and combination protocols: /glp1-therapy-mohali →
A structured, four-phase programme that tracks clinical outcomes — not just the number on a scale.
Full metabolic phenotyping. HbA1c, thyroid, kidney function, lipid profile. Cardiac assessment (Echo/TMT) for at-risk patients. History of thyroid C-cell tumours screened.
Mounjaro vs Ozempic vs Wegovy vs Rybelsus selected based on metabolic phenotype, cardiac profile, cost, and patient preference. No one-size-fits-all prescribing.
Careful dose escalation to target dose. Nausea, gastroparesis, and injection site reactions monitored. Existing diabetes medicines adjusted to avoid hypoglycaemia as GLP-1 takes effect.
HbA1c, lipid profile, kidney function, and weight tracked every three months. Treatment adjusted based on outcomes data — not patient-reported weight loss alone.
GLP-1 drugs (Mounjaro, Ozempic, Wegovy, Rybelsus) are not on the CGHS formulary — the drug cost is not covered. However, CGHS covers the specialist consultation with Dr. Bhansali (reimbursable with a Wellness Centre referral) and all monitoring tests — HbA1c, thyroid, kidney function, lipid profile, Echo, TMT — cashless at Gini's in-house lab during IPD stays or reimbursable on OPD basis.
For CGHS patients, the practical approach is to use CGHS to cover all monitoring costs (saving ₹4,000–6,000 per quarter) and pay privately for the drug itself. Dr. Bhansali will recommend the most cost-effective GLP-1 for your clinical situation.
15 minutes from central Chandigarh. Endocrinologist-led. Full metabolic assessment before any prescription. Mon–Sat, 10 AM–6 PM.